Prophylactic HPV vaccines

Journal of Clinical Pathology

Volumn 60, Issue 9, 2007, Pages 961-965

  Stanley, Margaret ^a  

^a Department of Pathology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONDYLOMA; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; NOTE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; TREATMENT INDICATION; UTERINE CERVIX CANCER; VACCINATION;

CANCER VACCINES; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SELECTION; UTERINE CERVICAL NEOPLASMS;

EID: 34548049115     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.040568     Document Type: Note

References (32)

1. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with gentital warts. J Clin Microbiol 1995;33:2058-63.
2. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
4. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25.
6. Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645-52.
7. Derkay CS, Darrow DH. Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 2000;33:1127-42.
8. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-19.
9. Stanley M. HPV vaccines. Best Pract Res Clin Obstet Gynaecol 2006;20:279-93.
10. Shope RE. Immunization of rabbits to infectious papillomatosis. J Exp Med 1937;65:607-24.
11. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-84.
12. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus like particles induce the formation of neutralizing antibodies and detect HPV specific antibodies in human sera. J Gen Virol 1994;75:2075-79.
13. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
14. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
15. Suzich JA, Ghim SJ, Palmer Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553- 57.
16. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.
17. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet 2006;367:1247-55.
18. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
19. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006;24(Suppl 3):S106-13.
20. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
21. Koutskv LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
22. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
23. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49.
24. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cotton tail rabbit papillomavirus (CRPV) can protect against experimentally CRPV infection. J Virol 1995;69:3959-63.
25. Ghim S, Newsome J, Bell J, et al. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 2000;68:147-51.
26. Nardelli Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with numan papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128-37.
27. Chen XS, Garcea RL, Goldberg I, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000;5:557-67.
28. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
29. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
30. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
31. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006;24(Suppl 3):S155-63.
32. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.